Pablo Altman

1.4k total citations
31 papers, 978 citations indexed

About

Pablo Altman is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Pablo Altman has authored 31 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 20 papers in Physiology and 4 papers in Immunology and Allergy. Recurrent topics in Pablo Altman's work include Chronic Obstructive Pulmonary Disease (COPD) Research (20 papers), Asthma and respiratory diseases (20 papers) and Respiratory and Cough-Related Research (9 papers). Pablo Altman is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (20 papers), Asthma and respiratory diseases (20 papers) and Respiratory and Cough-Related Research (9 papers). Pablo Altman collaborates with scholars based in United States, Switzerland and United Kingdom. Pablo Altman's co-authors include Robert Fogel, David Price, Pankaj Goyal, George E. Taffet, James F. Donohue, Mario Castro, María Christou, Thys van der Molen, Arnaud Bourdin and Jacob Franek and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, European Respiratory Journal and Thorax.

In The Last Decade

Pablo Altman

30 papers receiving 947 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pablo Altman United States	16	732	567	71	66	63	31	978
Silvia Tognella Italy	19	684 0.9×	542 1.0×	29 0.4×	102 1.5×	69 1.1×	56	904
Luís J. Nannini Argentina	19	1.0k 1.4×	855 1.5×	47 0.7×	20 0.3×	59 0.9×	47	1.3k
Christopher Burgess United Kingdom	9	391 0.5×	503 0.9×	50 0.7×	46 0.7×	160 2.5×	30	939
Andréanne Côté Canada	13	273 0.4×	299 0.5×	96 1.4×	39 0.6×	41 0.7×	48	609
Faisal Yunus Indonesia	13	489 0.7×	362 0.6×	23 0.3×	27 0.4×	85 1.3×	79	753
Füsun Yıldız Türkiye	14	389 0.5×	361 0.6×	27 0.4×	48 0.7×	80 1.3×	69	735
Cynthia Caracta United States	21	1.4k 1.8×	1.2k 2.1×	23 0.3×	109 1.7×	53 0.8×	92	1.7k
Germano Bettoncelli Italy	16	658 0.9×	458 0.8×	21 0.3×	74 1.1×	143 2.3×	38	916
Luis Manuel Entrenas Costa Spain	11	401 0.5×	403 0.7×	33 0.5×	86 1.3×	18 0.3×	33	995
Hugh H. Windom United States	14	472 0.6×	679 1.2×	30 0.4×	363 5.5×	76 1.2×	25	1.1k

Countries citing papers authored by Pablo Altman

Since Specialization

Citations

This map shows the geographic impact of Pablo Altman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Altman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Altman more than expected).

Fields of papers citing papers by Pablo Altman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Altman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Altman. The network helps show where Pablo Altman may publish in the future.

Co-authorship network of co-authors of Pablo Altman

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Altman. A scholar is included among the top collaborators of Pablo Altman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Altman. Pablo Altman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krishnan, Jamuna K., Gerard J. Criner, Fernando J. Martínez, et al.. (2025). Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 12(2). 127–136. 1 indexed citations

Krishnan, Jamuna K., et al.. (2024). Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 11(5). 472–481. 4 indexed citations

Wood, Robert A., R. Sharon Chinthrajah, Alexander Eggel, et al.. (2022). The rationale for development of ligelizumab in food allergy. World Allergy Organization Journal. 15(9). 100690–100690. 33 indexed citations

Gevaert, Philippe, et al.. (2022). Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). Journal of Allergy and Clinical Immunology. 149(5). 1675–1682.e3. 18 indexed citations

O’Byrne, Paul M., Reynold A. Panettieri, Christian Taube, et al.. (2022). Development of an inhaled anti-TSLP therapy for asthma. Pulmonary Pharmacology & Therapeutics. 78. 102184–102184. 21 indexed citations

Mall, Marcus, Gerard J. Criner, Marc Miravitlles, et al.. (2022). Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond. European Respiratory Journal. 61(4). 2201307–2201307. 24 indexed citations

Brightling, Christopher E., Swarupa G. Kulkarni, Bart N. Lambrecht, et al.. (2021). The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulmonary Pharmacology & Therapeutics. 68. 102030–102030. 6 indexed citations

Price, David, et al.. (2020). Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. European Respiratory Review. 29(155). 190151–190151. 87 indexed citations

Brightling, Christopher E., Guy Brusselle, & Pablo Altman. (2019). The impact of the prostaglandin D₂ receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy. 75(4). 761–768. 31 indexed citations

10.

Ntritsos, Georgios, Jacob Franek, Lazaros Belbasis, et al.. (2018). Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. International Journal of COPD. Volume 13. 1507–1514. 165 indexed citations

11.

D’Urzo, Anthony, Giovanni Bader, Steven S. Shen, Pankaj Goyal, & Pablo Altman. (2018). Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. npj Primary Care Respiratory Medicine. 28(1). 18–18. 6 indexed citations

12.

Altman, Pablo, et al.. (2018). Patient perception of Breezhaler^® and Ellipta^® device feedback mechanisms in COPD: The ADVANTAGE Study. Current Medical Research and Opinion. 35(2). 221–227. 4 indexed citations

13.

Rodrigo, Gustavo J., David Price, Antonio Anzueto, et al.. (2017). LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of COPD. Volume 12. 907–922. 113 indexed citations

14.

Donohue, James F., Keith A. Betts, Ella X. Du, et al.. (2017). Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. International Journal of COPD. Volume 12. 367–381. 21 indexed citations

15.

Kerwin, Edward, Kenneth R. Chapman, Marc Decramer, et al.. (2015). Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. International Journal of COPD. 10. 1599–1599. 18 indexed citations

16.

Vincken, Walter, Joseph Aumann, Pankaj Goyal, & Pablo Altman. (2014). Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study. European Respiratory Journal. 44(Suppl 58). P2410–P2410. 3 indexed citations

17.

Patalano, Francesco, Donald Banerji, Peter D’Andrea, et al.. (2014). Addressing unmet needs in the treatment of COPD. European Respiratory Review. 23(133). 333–344. 14 indexed citations

18.

Rossi, Andrea, Thys van der Molen, Alberto Papi, et al.. (2014). INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. European Respiratory Journal. 44(6). 1548–1556. 90 indexed citations

19.

Sharafkhaneh, Amir, Aylin Altan, Gene Colice, et al.. (2014). A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respiratory Medicine. 108(9). 1310–1320. 14 indexed citations

20.

Taffet, George E., James F. Donohue, & Pablo Altman. (2013). Considerations for managing chronic obstructive pulmonary disease in the elderly. Clinical Interventions in Aging. 9. 23–23. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact